VK2735 Guide
Viking Therapeutics' Dual GLP-1/GIP Agonist — Injectable & Oral
VK2735 is Viking Therapeutics' dual GLP-1/GIP receptor agonist developed for obesity in two formats: a once-weekly injectable (Phase 3 VANQUISH) and a once-daily oral tablet (Phase 2 VENTURE). It could become the first oral dual GLP-1/GIP agonist to reach market. Here's where the science and timeline stand.
What Is VK2735?
VK2735 is an investigational dual agonist that activates both the GLP-1 and GIP receptors — the same two-receptor strategy as tirzepatide (Mounjaro/Zepbound) — developed by Viking Therapeutics for chronic weight management. It is being advanced in two formulations: a once-weekly subcutaneous injection and a once-daily oral tablet.
The injectable is in Phase 3 (the VANQUISH program), while the oral tablet is in Phase 2 (the VENTURE program). Viking has stated it believes oral VK2735 has the potential to be the first oral dual GLP-1/GIP agonist to reach the market — a meaningful gap, since today's approved oral pills (orforglipron, oral semaglutide) are GLP-1 only.
Important: VK2735 is investigational and not FDA-approved. It is not available by prescription. Any "VK2735" sold by research-chemical or gray-market vendors is unverified, not the clinical compound, and not safe to use.
Clinical Trial Results
How VK2735 Works
Injectable vs Oral VK2735
| Feature | Injectable VK2735 | Oral VK2735 |
|---|---|---|
| Format | Subcutaneous injection | TabletBest |
| Frequency | Once weekly | Once daily |
| Lead Program | VANQUISH (Phase 3) | VENTURE (Phase 2) |
| Key Data | ~14.7% at 13 weeks | Up to 12.2% (26.6 lbs) at 13 weeks |
| Mechanism | GLP-1 / GIP dual agonist | GLP-1 / GIP dual agonist |
| Notable Goal | Compete with weekly injectables | Potential first oral dual GLP-1/GIP agonist |
| Status | Phase 3 ongoing | Phase 2; maintenance study expected H2 2026 |
Development Timeline
Guide FAQs
VK2735 is Viking Therapeutics' investigational dual GLP-1/GIP receptor agonist for obesity, developed in both a once-weekly injectable (VANQUISH, Phase 3) and a once-daily oral tablet (VENTURE, Phase 2). It is the same dual-incretin strategy as tirzepatide.
No. VK2735 is investigational and only available within clinical trials. It is not a prescription medication. Any VK2735 sold online by research-chemical vendors is unverified and unsafe.
In short Phase 2 trials, the injectable showed about 14.7% at 13 weeks and the oral tablet up to 12.2% (26.6 lbs) at 13 weeks with no plateau. Longer Phase 3 data will determine its ceiling versus approved drugs.
Both are dual GLP-1/GIP agonists. Zepbound (tirzepatide) is FDA-approved and widely available; VK2735 is investigational. Viking is also developing an oral version, which tirzepatide does not have.
Yes — if you are enrolled in a trial or your prescriber advises, Shotlee lets you log doses, weight, and side effects for any GLP-1 protocol, including investigational ones.
Track Any GLP-1 Protocol in Shotlee
Free dose logs, weight trends, and side-effect tracking — for approved and investigational GLP-1 medications alike.